Orphazyme A/S logo
Orphazyme A/S ORPH

Orphazyme A/S Balance Sheet 2011-2026 | ORPH

Annual Balance Sheet Orphazyme A/S

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-670 M -59.2 M -395 M -632 M -14.3 M -77.9 M -25.7 M - - -

Long Term Debt

23.8 M 51.6 M - - - - - - - -

Total Non Current Liabilities

35.3 M 61.8 M 105 K - - - - - - -

Total Current Liabilities

167 M 66 M 53 M 47.1 M 14.4 M 5.97 M 4.02 M - - -

Total Liabilities

202 M 128 M 53.1 M 47.1 M 14.4 M 5.97 M 4.02 M - - -

Retained Earnings

-1.5 B -899 M -565 M -338 M -212 M -127 M -94.9 M - - -

Total Assets

822 M 181 M 441 M 663 M 31.9 M 95.3 M 35.6 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Orphazyme A/S, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 3.02 1.0 % $ 258 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
BioNTech SE BioNTech SE
BNTX
$ 90.9 -0.31 % $ 27.2 B germanyGermany
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.34 5.72 % $ 908 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Codexis Codexis
CDXS
$ 1.93 6.04 % $ 168 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 1.9 1.88 % $ 362 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Cullinan Management Cullinan Management
CGEM
$ 15.2 5.34 % $ 916 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.69 -2.31 % $ 198 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.46 -13.46 % $ 5.27 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.11 -0.48 % $ 439 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 2.27 0.39 % $ 1.01 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.91 0.89 % $ 3.05 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.3 3.36 % $ 227 M israelIsrael
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.37 1.97 % $ 138 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.6 0.95 % $ 107 M usaUSA
Curis Curis
CRIS
$ 0.53 -3.64 % $ 6.98 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 38.09 2.31 % $ 3.58 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.43 -0.17 % $ 4.44 B schweizSchweiz
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.41 -3.4 % $ 608 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.87 1.26 % $ 5.85 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 0.17 -7.12 % $ 16.1 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.43 1.18 % $ 2.09 B usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 4.34 -29.51 % $ 10.9 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA